From Our Partners
Sunday, July 3, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

NMRC Researcher Is Awarded a Gates Foundation Grant

by Global Biodefense Staff
November 20, 2012

NMRC malaria researchA Naval Medical Research Center (NMRC) researcher was awarded a Bill & Melinda Gates Foundation Grand Challenges Exploration Opportunities Grant. Lt. Robert Gerbasi received a $100,000 grant with a potential follow-on grant of up to $1 million for his project that focuses on targeting the liver stage of malaria as a major component for a possible vaccine for deployed warfighters. 

“A military conflict or humanitarian crisis can arise in a malaria endemic area of the world at any time,” said Gerbasi. “If our warfighters are not protected from malaria they will be out of the fight pretty fast. We want to fight our adversary, not malaria and our adversary. I hope that over the long term this research identifies a new class of vaccine targets that can be used to protect service members and people who live in malaria endemic areas of the world.” 

The U.S. Military Malaria Vaccine Program (USMMVP) has aggressively pursued vaccine approaches to protect the warfighter from malaria. The Navy side of the USMMVP focuses on developing a vaccine that employs cell-mediated immunity by manipulating a specific cell type, the CD8T cell, to find and kill liver stage parasites. 

Infected mosquitoes inject malaria parasites when they bite an individual. The parasites travel to the liver, invade liver cells, multiply and develop into thousands of parasites that burst out of the liver cells and into the bloodstream and infect red blood cells. During the liver stage, malaria presents pieces of itself, in the form of short peptides, on the surface of the liver cells. 

“Our goal is to identify small pieces of malaria peptides,” said Gerbasi. “Those peptides would serve as excellent vaccine candidates to train an individual’s immune system to recognize and kill infected liver cells.” 

During the first six months of the project, Gerbasi and his team will work to identify thousands of peptides on the surface of infected liver cells. In the second phase of the project, they will identify the peptides that are immunogenic. In the final phase, Gerbasi will prepare the findings for presentation and publication. 

“If things go well with the first Grand Challenges project, I will be placed on a short list of investigators eligible for a second Grand Challenges award worth $1 million,” said Gerbasi. “I was pretty excited to have this proposal selected. The NMRC research program has an outstanding team of entomologists, microbiologists, biochemists and molecular biologists all working toward the goal of a vaccine. I am proud to be a member of the team.” 

The primary objective of the Navy malaria program is to develop a vaccine that kills the parasite during its first few days of development in the liver, before it breaks out into the blood. If this approach is successful, it will prevent the clinical manifestation of malaria, which occurs only in conjunction with blood-stage infection and not with the liver stage. Such a vaccine would benefit deployed military personnel as well as travelers and other populations. At the same time, the program is investigating vaccines that would target blood-stage infection to limit the severity of symptoms associated with this stage. Both liver and blood-stage vaccines, if deployed in endemic areas, could alleviate much of the suffering caused by this parasite in tropical countries. 

Article provided courtesy of Naval Medical Research & Development News. Image: Lt. Robert Gerbasi conducting malaria research at an NMRC laboratory, taken by Phil Collins.

From Our Partners
Tags: AwardsMalaria

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC